DailyIQ
DailyIQ
Last updatedUpdating…

GENB·Generate Biomedicines, Inc.

$13.00
+0.43 (+3.42%)
High
$13.43
Open
$12.92
Market Cap
1.82B
52W High
$22.67
Low
$12.47
P. Close
$13.00
P/E
-
52W Low
$11.00
Fwd P/E
-5.51
DailyIQ Est.
$27.93
Inst. Own.
4.9%
Short Interest
6.40%
Days to Cover
8.0
NewEarnings release, scored · filed Aug 6, 2026tone +1.7 vs prior release · 42 lines scoredSee the breakdown
Technical Score (1D)
50
NEUTRAL
News Sentiment
62
BULLISH
GENB scores 50 on the 1D technical view with a NEUTRAL signal and mixed momentum. Price action is in a neutral range - the market is coiling, and neither side has been willing to push to a definitive break. Sentiment at 62 is diverging from the flat technical backdrop, removing sentiment as a directional catalyst for now. Consolidations like this are often a sign that the market is waiting for new information before committing capital in either direction. The range between $12.63 and $13.69 is well-defined. When this kind of compression resolves - particularly if it resolves with a gap or range-expansion bar - the follow-through tends to be more sustained than a typical breakout because of the energy that builds during the quiet phase. Coiled setups like this are as much about time as they are about price - the longer GENB compresses between $12.63 and $13.69 without a catalyst, the more the eventual move tends to compensate. Watching for a volume spike on the actual break, rather than trying to anticipate direction from the shape of the range, has historically been the more reliable approach.
LOW TARGET
$22 +69.2%
1 analysts
MEAN TARGET
$27 +107.7%
7 analysts
HIGH TARGET
$30 +130.8%
6 analysts
PRICE RANGE
$22.00 - $30.00
SB / B / H / S / SS
3/8/1/1/1
DAILYIQ EST.
$27.93 (+114.8%)
Bought (1Y)
0 shares
$0
Sold (1Y)
12,409 shares
$201K
ARNOLD FRANCES-
Sell11,409 shares2026-10-29
ARNOLD FRANCES-
Sell1,000 shares2026-09-01

EPS

EstBeatMiss
$-1.15$-0.97$-0.79$-0.61$-0.42Q1'26Q3'26
QtrEstActual+/−
Q3'26$-0.55 - -
Q1'26$-0.51$-1.07-111.2%

Revenue

EstBeatMiss
$7M$7M$7M$8M$8MQ1'26Q3'26
QtrEstActual+/−
Q3'26$8M - -
Q1'26 - $7M -

Market Data

GENB Stock Snapshot

NEUTRAL50/100
$13.00+$0.43 (3.4%)
Market cap
1.82B
Day range
$12.47 – $13.43
News sentiment
62/100 · Bullish
Analyst target
$27.00 (+107.7%)
Consensus
Buy · 14 analysts
52-week range+18.2% off low · -42.7% from high
$11.00$22.67
Price $13.00 DailyIQ Est. $27.93

The technical read on GENB is balanced, which usually means the market is waiting on a catalyst. Thinner liquidity means moves can extend past what the fundamentals alone justify.

Sector Rotation

Is money rotating into or out of GENB's sector?

Generate Biomedicines, Inc. sits in the Health Care sector, currently ranked 1st of 12 GICS sectors by relative-strength rotation score (weakening). Within its narrower Biotechnology industry group, GENB ranks 7th of 15 tracked industries, weakening.

Sector rank
#1 of 12
Sector state
Weakening
Sector rotation score
100
Industry rank
#7 of 15

Options Market

What is the options market pricing for GENB?

CallsPuts

For Generate Biomedicines, Inc.'s nearest expiry (2026-11-20, 14 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.19), with at-the-money implied volatility around 100.8%. The options market is pricing roughly a ±19.6% move by that expiry — a range of about $10.41–$15.49.

Put/call ratio (2026-11-20)
0.19
ATM implied volatility
100.8%
Total open interest
1,731
Expected move by 2026-11-20
±19.6% ($10.41–$15.49)

Analyst Consensus Estimates

What do analysts expect GENB to earn?

Analysts expect Generate Biomedicines, Inc. to earn -$2.30 per share in the fiscal year ending Dec 2026 and -$2.28 in the fiscal year ending Dec 2027, from 4 estimates. These are analyst forecasts, not company guidance, and later years rest on fewer analysts.

Quarter endingEPS estimateEPS rangeEPS analystsRevenue estimateRevenue analysts
Sep 2026-$0.55-$0.67 to -$0.444$8M5
Dec 2026-$0.57-$0.63 to -$0.444$8M5
Mar 2027-$0.55-$0.63 to -$0.433--
Jun 2027-$0.53-$0.68 to -$0.413--
Sep 2027-$0.52-$0.68 to -$0.363--
Fiscal year endingEPS estimateEPS rangeEPS analystsRevenue estimateRevenue analysts
Dec 2026-$2.30-$2.50 to -$2.144$30M6
Dec 2027-$2.28-$2.72 to -$1.534$24M6

Analyst Rating Changes

Are analysts turning bullish or bearish on GENB?

HC Wainwright & Co. most recently reiterated its rating on Generate Biomedicines, Inc. to Buy on Oct 5, 2026 with a price target of $30. Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
HC Wainwright & Co.: Buy
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Oct 5, 2026HC Wainwright & Co.ReiteratedBuy$30
Sep 8, 2026HC Wainwright & Co.ReiteratedBuy$30
Aug 28, 2026HC Wainwright & Co.MaintainedBuy$25 → $30
May 14, 2026Morgan StanleyMaintainedOverweight$20 → $22
May 8, 2026HC Wainwright & Co.MaintainedBuy$16 → $25
Apr 13, 2026HC Wainwright & Co.InitiatedBuy$16
Mar 24, 2026Goldman SachsInitiatedBuy$26
Mar 24, 2026Morgan StanleyInitiatedOverweight$20
Mar 24, 2026Piper SandlerInitiatedOverweight$24
Mar 24, 2026Cantor FitzgeraldInitiatedOverweight-
Mar 24, 2026GuggenheimInitiatedBuy$30

Corporate Stakes

Which companies own a stake in GENB?

0.60%held by NVDA

NVIDIA Corporation reports a stake in Generate Biomedicines, Inc. on SEC Form 13F: 833.3K shares, about 0.60% of the company, worth $14.1M at the end of Q2 2026. At today's price that stake is worth $10.8M, about 0.00% of NVDA's own market value.

Holder
NVDA
Shares held
833.3K
Stake
0.60%
Value
$14.1M
HolderLast quarterShares% of GENBValue at filingValue nowChange
NVIDIA Corporation NVDAUnchanged833.3K0.60%$14.1M$10.8M-22.9%

Form 13F lists US-listed shares held at quarter-end and is filed up to 45 days later. Stakes in private companies are not on it. Value now and Change put those same shares, adjusted for any stock split, at today's price against their reported quarter-end value, so they do not reflect buying or selling since.

Earnings Release, Scored

What did Generate Biomedicines, Inc.'s latest earnings release say?

Filed Aug 6, 2026 · SEC Form 8-K, Exhibit 99

Tone67.5/ 100+1.7 vs prior release
Hedging words0.23per 100 words-0.14 vs prior release
Tone, last 2 releasesScale 50–73

Most important lines

  1. 1

    Revenue for the quarter ended June 30, 2026, was $6.3 million, compared with $10.1 million for the same period in 2025.

  2. 2

    Net loss was $67.3 million for the quarter ended June 30, 2026, compared with $56.7 million for the same period in 2025, which includes noncash, stock-based compensation expense of $8.2 million and $5.5 million, respectively.

    Negative tone
  3. 3

    Net cash used in operating activities was $138.3 million for the six months ended June 30, 2026, compared with $101.9 million for the six months ended June 30, 2025.

ETF holders

ETFs holding GENB

News & sentiment

What is the news saying about GENB?

GENB fell 7.1% over the month to Nov 6. Daily news tone ranged from 48 to 96 and read 50 on Oct 28.

Daily close and news tone, Oct 6 to Nov 6
$12$14Oct 6Oct 7Oct 8Oct 9Oct 12Oct 13: tone 48Oct 14: tone 96Oct 15Oct 16Oct 19Oct 20Oct 21Oct 22: tone 54Oct 23Oct 26Oct 27Oct 28: tone 50Oct 29Oct 30Nov 2Nov 3Nov 4Nov 5Nov 6Oct 6News toneNov 6123
  1. Oct 27 +9.1%
  2. Oct 28 +15.1%same day: Anthropic Says Claude Helped Generate 35,000 Drug Designs, Cut Drug Development Workloads
  3. Nov 5 -11.2%
Latest stories naming Generate Biomedicines

Technical analysis

How strong is GENB's momentum right now?

On the daily chart GENB ranks at the 50th percentile for momentum against the stocks and ETFs DailyIQ tracks, a neutral reading.

Momentum rank by timeframe0 = weakest, 100 = strongest
See what drives the rankThe inputs behind each timeframe's momentum rank, plus RSI, stochastics, Bollinger Bands and moving averages. Free with an account.

Institutional ownership

Are big funds buying or selling GENB?

28 of the 39 tracked managers added to GENB in their latest 13F and 9 trimmed. Together they own 4.3% of the company, worth $101.2M. Baker Bros. Advisors and ARK Investment Management alone hold 1.9%.

28adding9trimming2unchanged
Largest holders by stake, latest 13FBar = share of GENB
  1. $24.0M positionUnchanged last quarter
  2. $21.7M positionAdded 157.7% last quarter
  3. $19.1M positionAdded 762.6% last quarter
  4. $8.9M positionNew position last quarter
  5. $5.5M positionTrimmed 8.5% last quarter
  6. $3.8M positionNew position last quarter
  7. $3.0M positionAdded 904.6% last quarter
  8. $2.8M positionNew position last quarter
  9. $2.0M positionAdded 64.9% last quarter
  10. $1.7M positionUnchanged last quarter
Full holdings history

Discover more

How has GENB done against its peers?

Over the six months to Nov 6, GENB returned −13.3%. Of the 15 related stocks and ETFs, 14 did better, led by MRNA at +426.3%.

Change since May 6, through Nov 6
−200%0%+200%+400%+600%May 6JunJulAugSepOctNov 6MRNA +426.3%GENB −13.3%INSM −20.8%